Congrès et publications

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies BGB-16673, a BTK degrader, overcomes on-target resistance from BTK inhibitors and presents sustainable long-term tumor regression in lymphoma xenograft models Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors (BTKi) Characterization of zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database Comparative efficacy of zanubrutinib (zanu) versus rituximab (rtx) in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC) Efficacy and safety of once daily (QD) vs twice daily (BID) zanubrutinib for patients with various B-cell malignancies: a comparative summary of clinical data and exposure-response analysis First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): results from the phase 3 ASPEN trial long-term follow-up Long-term efficacy and safety of zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Matching-adjusted indirect comparison (MAIC) of zanubrutinib (zanu) versus ibrutinib (ibru) in relapsed/refractory marginal zone lymphoma (R/R MZL) Persistent with oral therapy as reflection of actual compliance for chronic lymphocytic leukemia (CLL) - a national prescribed drug and patient registered study from Sweden Real-world treatment patterns of Bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US) The meta-analytic endpoint validation of surrogates used in clinical trials evaluating the efficacy of therapies in patients with chronic lymphocytic leukemia Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)

Results from the pivotal phase 2b HERIZON-BTC-01 study: zanidatamab in previously-treated HER2‑amplified biliary tract cancer (BTC)

A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC) Comparative efficacy of zanubrutinib (ZANU) versus rituximab (RTX) in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC) First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS) MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL) Real-world treatment patterns of Bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US) Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: zanidatamab in previously- treated HER2-amplified biliary tract cancer (BTC) Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): the RATIONALE-301 European/North American (EU/NA) subgroup Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a Phase Ib/II study Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study

Literature review of statistical methods comparisons through simulations when using external control arm for regulatory or HTA submissions

Literature review of statistical methods comparisons through simulations when using external control arm for regulatory or HTA submissions

Preliminary safety and efficacy of BGB-11417 (novel Bcl-2 inhibitor) in combination with azacitidine in AML Rate of cardiac disorders in patients with B-cell malignancies who undergo treatment with zanubrutinib Zanubrutinib demonstrates superior progression-free survival vs ibrutinib for relapsed/refractory CLL/SLL: ALPINE final analysis Zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MZL): final analysis of MAGNOLIA (BGB-3111-214)

BGB-11417 (Bcl-2 inhibitor) monotherapy or combination therapy with zanubrutinib in non-Hodgkin lymphoma or Waldenström macroglobulinemia patients BGB-11417 (Bcl-2 inhibitor) monotherapy or combination with zanubrutinib in CLL/SLL patients: preliminary phase 1 data Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 Study Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies

BGB-11417 (Bcl-2 inhibitor) monotherapy or combination therapy with zanubrutinib in non-Hodgkin lymphoma or Waldenström macroglobulinemia patients BGB-11417 (Bcl-2 inhibitor) monotherapy or combination with zanubrutinib in CLL/SLL patients: preliminary phase 1 data Preliminary safety and efficacy of BGB-11417 (novel Bcl-2 inhibitor) in combination with azacitidine in AML Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 Study Rate of cardiac disorders in patients with B-cell malignancies who undergo treatment with zanubrutinib Zanubrutinib demonstrates superior progression-free survival vs ibrutinib for relapsed/refractory CLL/SLL: ALPINE final analysis Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies Zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MZL): final analysis of MAGNOLIA (BGB-3111-214)

A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors

Association of tumor mutational burden (TMB) and clinical outcomes with tislelizumab versus chemotherapy in esophageal squamous cell carcinoma (ESCC) from RATIONALE-302. BGB-24714, a novel oral IAP antagonist, displayed significant anti-tumor activities in preclinical models as a monotherapy and in combination with paclitaxel Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) + chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis

A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors Association of tumor mutational burden (TMB) and clinical outcomes with tislelizumab versus chemotherapy in esophageal squamous cell carcinoma (ESCC) from RATIONALE-302. BGB-24714, a novel oral IAP antagonist, displayed significant anti-tumor activities in preclinical models as a monotherapy and in combination with paclitaxel Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) + chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors

BGB-11417 (Bcl-2 Inhibitor) monotherapy or combination with zanubrutinib in CLL/SLL patients: preliminary phase 1 data Zanubrutinib demonstrates superior progression-free survival versus ibrutinib for relapsed/refractory CLL/SLL: ALPINE final analysis

A phase 1 study with the novel B-cell lymphoma 2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin lymphoma or Waldenström ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial

A phase 1 study with the novel B-cell lymphoma (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data A phase 1 study with the novel B-cell lymphoma (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin's lymphoma or Waldenström macroglobulinemia ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of MAGNOLIA (BGB-3111-214) trial Zanubrutinib demonstrates superior progression-free survival versus ibrutinib for relapsed/refractory CLL/SLL: ALPINE final analysis